Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Rehabilitation interventions vs no treatment or control Activities of daily living (primary outcome) · stroke survivors with vision perception disorders Interventions for perceptual disorders following stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Rehabilitation interventions vs no treatment or control Extended activities of daily living · stroke survivors with hearing, smell, and taste perception disorders Interventions for perceptual disorders following stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Rehabilitation interventions vs no treatment or control Extended activities of daily living (Analysis 5.1) · stroke survivors with vision perception disorders Interventions for perceptual disorders following stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Rehabilitation interventions vs no treatment or control Quality of life and participation · stroke survivors with vision perception disorders Interventions for perceptual disorders following stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Rehabilitation interventions vs no treatment or control Psychological and mental health · stroke survivors with vision perception disorders Interventions for perceptual disorders following stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Rehabilitation interventions vs no treatment or control Adverse events · stroke survivors with vision perception disorders Interventions for perceptual disorders following stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Rehabilitation interventions vs no treatment or control Quality of life and participation · stroke survivors with hearing, smell, and taste perception disorders Interventions for perceptual disorders following stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Rehabilitation interventions vs no treatment or control Psychological and mental health · stroke survivors with hearing, smell, and taste perception disorders Interventions for perceptual disorders following stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Rehabilitation interventions vs no treatment or control Perception · stroke survivors with hearing, smell, and taste perception disorders Interventions for perceptual disorders following stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Rehabilitation interventions vs no treatment or control Adverse events · stroke survivors with hearing, smell, and taste perception disorders Interventions for perceptual disorders following stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Rehabilitation interventions vs no treatment or control CI: confidence interval · stroke survivors with hearing, smell, and taste perception disorders Interventions for perceptual disorders following stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Rehabilitation interventions vs no treatment or control Activities of daily living ‐ intervention for not Pusher Syndrome (Analysis 1.1) (primary outcome) · stroke survivors with somatosensory perception disorders Interventions for perceptual disorders following stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Rehabilitation interventions vs no treatment or control Extended activities of daily living · stroke survivors with somatosensory perception disorders Interventions for perceptual disorders following stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Tacrolimus vs ciclosporin Serious adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis Tacrolimus (FK506) for induction of remission in corticosteroid‐refractory ulcerative colitis (2022) · Cochrane | no estimate extracted | NR | No studies |
Tacrolimus vs ciclosporin Total adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis Tacrolimus (FK506) for induction of remission in corticosteroid‐refractory ulcerative colitis (2022) · Cochrane | no estimate extracted | NR | No studies |
Shared decision‐making interventions vs usual care Adverse events ‐ not reported · people with mental health conditions Shared decision‐making interventions for people with mental health conditions (2022) · Cochrane | no estimate extracted | NR | No studies |
Increased vs stable doses of inhaled corticosteroids Outcomes* · adults and children with chronic asthma Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and… (2022) · Cochrane | no estimate extracted | NR | No studies |
Ultra‐radical (extensive) surgery vs standard surgery Recurrence rate · women with stage IIIc or IV ovarian cancer Ultra‐radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced… (2022) · Cochrane | no estimate extracted | NR | No studies |
Ultra‐radical (extensive) surgery vs standard surgery (Loco)regional control · women with stage IIIc or IV ovarian cancer Ultra‐radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced… (2022) · Cochrane | no estimate extracted | NR | No studies |
Ultra‐radical (extensive) surgery vs standard surgery Quality of Life · women with stage IIIc or IV ovarian cancer Ultra‐radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced… (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with chemotherapy vs chemotherapy alone Outcomes · newly‐diagnosed EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs chemotherapy Outcomes · platinum‐sensitive recurrent EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs placebo after chemotherapy (maintenance therapy) Outcomes · platinum‐sensitive recurrent EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with chemotherapy vs chemotherapy alone Overall survival ‐ not reported · newly‐diagnosed EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi with chemotherapy vs chemotherapy alone Outcomes · platinum‐sensitive recurrent EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi with chemotherapy vs chemotherapy alone Quality of Life ‐ not reported · platinum‐sensitive recurrent EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi monotherapy vs chemotherapy Outcomes · platinum‐resistant recurrent EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi monotherapy vs chemotherapy Overall survival ‐ not reported · platinum‐resistant recurrent EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi monotherapy vs chemotherapy Progression‐free survival ‐ not reported · platinum‐resistant recurrent EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi monotherapy vs chemotherapy Quality of Life ‐ not reported · platinum‐resistant recurrent EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy vs placebo (maintenance therapy) Outcomes · newly‐diagnosed EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Intratympanic plus systemic corticosteroids (combined therapy) vs systemic corticosteroids alone Adverse eventsb · sudden sensorineural hearing loss Intratympanic corticosteroids for sudden sensorineural hearing loss (2022) · Cochrane | no estimate extracted | NR | No studies |
Intratympanic plus systemic corticosteroids (combined therapy) vs systemic corticosteroids alone Vertigo/dizziness: timing not reported · sudden sensorineural hearing loss Intratympanic corticosteroids for sudden sensorineural hearing loss (2022) · Cochrane | no estimate extracted | NR | No studies |
Intratympanic plus systemic corticosteroids (combined therapy) vs systemic corticosteroids alone Ear pain: timing not reported · sudden sensorineural hearing loss Intratympanic corticosteroids for sudden sensorineural hearing loss (2022) · Cochrane | no estimate extracted | NR | No studies |
Intratympanic corticosteroids vs no treatment or versus placebo Adverse eventsb · sudden sensorineural hearing loss Intratympanic corticosteroids for sudden sensorineural hearing loss (2022) · Cochrane | no estimate extracted | NR | No studies |
Intratympanic corticosteroids vs no treatment or versus placebo Vertigo/dizziness: timing not reported · sudden sensorineural hearing loss Intratympanic corticosteroids for sudden sensorineural hearing loss (2022) · Cochrane | no estimate extracted | NR | No studies |
Intratympanic corticosteroids vs no treatment or versus placebo Ear pain: timing not reported · sudden sensorineural hearing loss Intratympanic corticosteroids for sudden sensorineural hearing loss (2022) · Cochrane | no estimate extracted | NR | No studies |
Intratympanic plus systemic corticosteroids (combined therapy) vs systemic corticosteroids alone Change in hearing threshold determined by PTA · sudden sensorineural hearing loss Intratympanic corticosteroids for sudden sensorineural hearing loss (2022) · Cochrane | no estimate extracted | NR | No studies |
Intratympanic plus systemic corticosteroids (combined therapy) vs systemic corticosteroids alone Final hearing threshold determined by PTA · sudden sensorineural hearing loss Intratympanic corticosteroids for sudden sensorineural hearing loss (2022) · Cochrane | no estimate extracted | NR | No studies |
Intratympanic plus systemic corticosteroids (combined therapy) vs systemic corticosteroids alone Adverse eventsb · sudden sensorineural hearing loss Intratympanic corticosteroids for sudden sensorineural hearing loss (2022) · Cochrane | no estimate extracted | NR | No studies |
Intratympanic plus systemic corticosteroids (combined therapy) vs systemic corticosteroids alone Vertigo/dizziness: timing not reported · sudden sensorineural hearing loss Intratympanic corticosteroids for sudden sensorineural hearing loss (2022) · Cochrane | no estimate extracted | NR | No studies |
Intratympanic plus systemic corticosteroids (combined therapy) vs systemic corticosteroids alone Vertigo/dizziness: at the time of injection · sudden sensorineural hearing loss Intratympanic corticosteroids for sudden sensorineural hearing loss (2022) · Cochrane | no estimate extracted | NR | No studies |
Intratympanic plus systemic corticosteroids (combined therapy) vs systemic corticosteroids alone Ear pain: timing not reported · sudden sensorineural hearing loss Intratympanic corticosteroids for sudden sensorineural hearing loss (2022) · Cochrane | no estimate extracted | NR | No studies |
Intratympanic plus systemic corticosteroids (combined therapy) vs systemic corticosteroids alone Ear pain: at the time of injection · sudden sensorineural hearing loss Intratympanic corticosteroids for sudden sensorineural hearing loss (2022) · Cochrane | no estimate extracted | NR | No studies |
Intratympanic corticosteroids vs systemic corticosteroids Adverse eventsb · sudden sensorineural hearing loss Intratympanic corticosteroids for sudden sensorineural hearing loss (2022) · Cochrane | no estimate extracted | NR | No studies |
Low vs high 17ß‐oestradiol dose Endometrial histology · young women with Turner syndrome who have completed pubertal induction Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency (2022) · Cochrane | no estimate extracted | NR | No studies |
Low vs high 17ß‐oestradiol dose Uterine perfusion · young women with Turner syndrome who have completed pubertal induction Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency (2022) · Cochrane | no estimate extracted | NR | No studies |
Low vs high 17ß‐oestradiol dose Reproductive outcomes · young women with Turner syndrome who have completed pubertal induction Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency (2022) · Cochrane | no estimate extracted | NR | No studies |
Oral vs vaginal administration of oestradiol and dydrogesterone Endometrial histology · women with premature ovarian insufficiency (POI) awaiting oocyte donation Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency (2022) · Cochrane | no estimate extracted | NR | No studies |
Oral vs vaginal administration of oestradiol and dydrogesterone Uterine perfusion · women with premature ovarian insufficiency (POI) awaiting oocyte donation Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency (2022) · Cochrane | no estimate extracted | NR | No studies |